The DOI matches its Crossref record; 263 of the 263 references it cites were found in a registry or an index.
Mouse and human FcR effector functions
Abstract
Summary: Mouse and human FcRs have been a major focus of attention not only of the scientific community, through the cloning and characterization of novel receptors, and of the medical community, through the identification of polymorphisms and linkage to disease but also of the pharmaceutical community, through the identification of FcRs as targets for therapy or engineering of Fc domains for the generation of enhanced therapeutic antibodies. The availability of knockout mouse lines for every single mouse FcR, of multiple or cell‐specific—‘à la carte’—FcR knockouts and the increasing generation of hFcR transgenics enable powerful in vivo approaches for the study of mouse and human FcR biology. This review will present the landscape of the current FcR family, their effector functions and the in vivo models at hand to study them. These in vivo models were recently instrumental in re‐defining the properties and effector functions of FcRs that had been overlooked or discarded from previous analyses. A particular focus will be made on the (mis)concepts on the role of high‐affinity IgG receptors in vivo and on results from antibody engineering to enhance or abrogate antibody effector functions mediated by FcRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Antibody-based therapy FccRI / • Reduced antitumor mAb therapy of liver and lung metastatic melanoma (66, 195, 248) • Reduced anti-CD20 mAb lymphoma depletion (249) FccRIIB / • Increased mAb-induced antitumor therapy (133, 249, 250) • Impaired anti-inflammatory effects of intravenous immunoglobulin (IVIG) (76, 251–253…”
BackgroundFcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,680
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Self-citationRavetch, J. V., & Kinet, J. P. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.002325 · Cited by 1,229
Daëron, M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.203 · Cited by 1,227
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
IgE in allergy and asthma today
Gould, H. J., & Sutton, B. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2273 · Cited by 1,136
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Neutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 653
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
Junqueira, C., Crespo, Â., Ranjbar, S., de Lacerda, L. B., Lewandrowski, M., Ingber, J., Parry, B., Ravid, S., Clark, S., Schrimpf, M. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04702-4 · Cited by 631
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557
Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200785 · Cited by 549
The pathophysiology of anaphylaxis
Reber, L. L., Hernandez, J. D., & Galli, S. J. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.003 · Cited by 507
SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
Veillette, A., & Chen, J. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.12.005 · Cited by 476
Dekkers, G., Treffers, L., Plomp, R., Bentlage, A. E. H., de Boer, M., Koeleman, C. A. M., Lissenberg-Thunnissen, S. N., Visser, R., Brouwer, M., Mok, J. Y., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00877 · Cited by 356
ImmGen report: sexual dimorphism in the immune system transcriptome
Gal-Oz, S. T., Maier, B., Yoshida, H., Seddu, K., Elbaz, N., Czysz, C., Zuk, O., Stranger, B. E., Ner-Gaon, H., & Shay, T. (2019) · Nature Communications · doi:10.1038/s41467-019-12348-6 · Cited by 274
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Human IgE-independent systemic anaphylaxis
Finkelman, F. D., Khodoun, M. V., & Strait, R. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.02.015 · Cited by 299
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Affinity of human IgG subclasses to mouse Fc gamma receptors
Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T., & Vidarsson, G. (2017) · mAbs · doi:10.1080/19420862.2017.1323159 · Cited by 293
Ben Mkaddem, S., Benhamou, M., & Monteiro, R. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00811 · Cited by 283
IVIG-mediated effector functions in autoimmune and inflammatory diseases
Galeotti, C., Kaveri, S. V., & Bayry, J. (2017) · International Immunology · doi:10.1093/intimm/dxx039 · Cited by 269
IgA: Structure, Function, and Developability
de Sousa-Pereira, P., & Woof, J. M. (2019) · Antibodies · doi:10.3390/antib8040057 · Cited by 264
Irrgang, P., Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil, M., Beileke, S., Schäfer, S., Zhong, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade2798 · Cited by 264
Cloutier, N., Allaeys, I., Marcoux, G., Machlus, K. R., Mailhot, B., Zufferey, A., Levesque, T., Becker, Y., Tessandier, N., Melki, I., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720553115 · Cited by 219
“Thus, IC-mediated responses in mice strongly favor leukocytes, which express other FcγRs, while platelets play small or accessory roles in mouse models implicating ICs.”
BackgroundMethodInfluentialWada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
Tau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90
Asthagiri Arunkumar, G., Ioannou, A., Wohlbold, T. J., Meade, P., Aslam, S., Amanat, F., Ayllon, J., García-Sastre, A., & Krammer, F. (2019) · Journal of Virology · doi:10.1128/jvi.01696-18 · Cited by 80
Hansen, I. S., Hoepel, W., Zaat, S. A. J., Baeten, D. L. P., & den Dunnen, J. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700883 · Cited by 69
Acharya, D., Li, X. R. (., Heineman, R. E.-S., & Harrison, R. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03049 · Cited by 66
“The ligation of IgG-opsonized particles to FcγRs leads to receptor crosslinking which activates Src tyrosine kinase resulting in tyrosine phosphorylation of the ITAM motif (8).”
BackgroundInfluentialStarkl, P., Watzenboeck, M. L., Popov, L. M., Zahalka, S., Hladik, A., Lakovits, K., Radhouani, M., Haschemi, A., Marichal, T., Reber, L. L., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.002 · Cited by 59
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., Amit, I., & Dahan, R. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8005 · Cited by 39
Khare, P., Challa, D. K., Devanaboyina, S. C., Velmurugan, R., Hughes, S., Greenberg, B. M., Ober, R. J., & Ward, E. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.09.002 · Cited by 31
Illouz, T., Nicola, R., Ben-Shushan, L., Madar, R., Biragyn, A., & Okun, E. (2021) · Communications Biology · doi:10.1038/s42003-021-01851-6 · Cited by 21
Tang, Z.-M., Yuan, P., Gao, N., Lei, J.-G., Ahmed, M., Hua, Y.-X., Yang, Z.-R., Li, Q.-Y., & Li, H.-Y. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.02.008 · Cited by 4
Metadata
- Authors
- Bruhns, P., & Jönsson, F.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2015-10-26
- Volume
- 268
- Issue
- 1
- Pages
- 25-51
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W1862569453
- Cited by
- 579
- References
- 263
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.